Back to search

Article

Design, synthesis and profiling of highly potent antivirals targeting emerging drug-resistant HIV-1 variants

2025-12-30

Abstract excerpt

<h4> Abstract </h4> Lenacapavir (LEN), the first-in-class HIV capsid inhibitor (CAI), is approved by FDA as a long acting injectable (LAI) for both treatment and pre-exposure prophylaxis (PrEP). Despite its exceptional potency and long pharmacokinetics (PK), a few major resistant mutations have been selected in LEN-treated patients, underscoring the need to develop second-generation LEN analogs to mitigate resis...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d7c9e648-db68-5e77-b3d4-93fe41db4984
DOI
10.64898/2025.12.29.696941
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Design, synthesis and profiling of highly potent antivirals targeting emerging drug-resistant HIV-1 variantsDOI 10.64898/2025.12.29.696941
Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to LenacapavirSemantic proximity
Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir.Semantic proximity
Design and Synthesis of New GS-6207 Subtypes for Targeting HIV-1 Capsid Protein.Semantic proximity
Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavirSemantic proximity
Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences.Semantic proximity
Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.Semantic proximity
From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infectionSemantic proximity
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04Semantic proximity
Combating Antiviral Drug Resistance: A Multipronged Strategy.Semantic proximity
HIV Capsid is a Tractable Target for Small Molecule Therapeutic InterventionSemantic proximity
The RdRp Thumb-1 Pocket is a Conserved Target for Broad-Spectrum Antiviral DevelopmentSemantic proximity
A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsidSemantic proximity
Select a neighboring publication to make it the new centre.